scout
Commentary|Videos|December 8, 2024

Dr Jurczak on the Efficacy and Safety of Nemtabrutinib in R/R Follicular Lymphoma

Wojciech Jurczak, MD, PhD, discusses the safety and efficacy of nemtabrutinib, a noncovalent reversible BTK inhibitor in relapsed or refractory follicular lymphoma.

Wojciech Jurczak, MD, PhD, Department of Clinical Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, discusses findings from the phase 2 BELLWAVE-003 study (NCT04728893) of nemtabrutinib in relapsed or refractory follicular lymphoma. These findings were presented at the 2024 ASH Annual Meeting.

Newsletter

Stay up to date on the most recent and practice-changing oncology data


Latest CME